Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
AN3-H52H3 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
AN3-M52H3 | Mouse | Mouse Angiopoietin-like 3 / ANGPTL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
AN3-H82E7 | Human | Biotinylated Human Angiopoietin-like 3 / ANGPTL3 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
AN3-H5226 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Evinacumab | REGN-1500 | Approved | Regeneron Pharmaceuticals Inc | Evkeeza | EU | Hypercholesterolemia | Regeneron Ireland Designated Activity Company | 2021-02-11 | Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Hypercholesterolemia; Metabolic Diseases | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
LY-3561774 | LY-3561774; DCR-CM-1; DCR-CM1 | Phase 1 Clinical | Dyslipidemias; Metabolic Diseases; Cardiovascular Diseases | Details | |
LY-3475766 | LY-3475766 | Phase 1 Clinical | Eli Lilly And Company | Dyslipidemias | Details |
ARO-APOC3 | ARO-APOC3 | Phase 3 Clinical | Arrowhead Pharmaceuticals | Hypertriglyceridemia; Hyperlipoproteinemia Type I | Details |
ARO-ANG3 | ARO-ANG3 | Phase 2 Clinical | Arrowhead Pharmaceuticals | Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Dyslipidemias; Hyperlipoproteinemia Type II; Lipid Metabolism Disorders | Details |
Vupanorsen | ISIS-703802; PF-07285557 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Hyperlipoproteinaemia type IIa; Hyperlipoproteinemia Type I; Dyslipidemias; Hyperlipoproteinemias; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
LNA-043 | LNA-043 | Phase 2 Clinical | Novartis Pharma Ag | Knee Injuries; Osteoarthritis, Knee; Osteoarthritis; Wounds and Injuries | Details |
This web search service is supported by Google Inc.